Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2018

View Archived Issues

Liquidia Technologies begins phase III study of LIQ-861

Mosedipimod receives FDA orphan drug designation for ARS

Cantex's CX-01 given FDA orphan drug status for AML

Deciphera Pharmaceuticals' INVICTUS study of DCC-2618 begins

First patient treated in phase I study of IMGN-632

Kura presents phase II results of tipifarnib in patients with CMML

AmpliPhi Biosciences reports topline results from expanded access program for AB-SA01 and AB-PA01

Asana BioSciences' ASN-002 shows efficacy in atopic dermatitis in proof-of-concept study

Audentes Therapeutics announces interim results from ASPIRO study of AT-132

Cortexyme begins phase I program for Alzheimer's disease candidate

Enrollment begins in phase II/III program for Catalyst Biosciences' marzeptacog alfa

Alovudine, a POLG inhibitor, shows promise for treating AML

Boston Pharmaceuticals obtains rights to Pierre Fabre drug candidate for atrial fibrillation

Janssen Pharmaceutica patents novel PI3Kbeta inhibitors

FDA awards fast track designation to tafenoquine for malaria

LifeArc and Suzhou Yabao Pharmaceutical divulge LRRK2 inhibitors

Shire receives FDA breakthrough therapy designation for maribavir

Takeda set to acquire TiGenix

Roche discloses new TLR8 agonists

WHO prequalifies first typhoid conjugate vaccine

BioMarin Pharmaceutical presents novel CGT inhibitors

GeneCentric and G1 Therapeutics establish research collaboration for drug response biomarkers

Novel KDM5B inhibitors described in Chrysalis patent

BriaCell updates progress of Bria-IMT trials

GeoVax collaborates with Vaxeal to expand cancer immunotherapy program

iTeos Therapeutics regains rights to EOS-200271 from Pfizer

Anti-GD2 CART approach shows promise for neuroblastoma treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...